BRIEF-Intellipharmaceutics says Rexista results indicate no food effect
July 5 (Reuters) - Intellipharmaceutics International Inc :
* Intellipharmaceutics reports update on Rexista XR: FDA grants waiver of NDA filing fee, and topline pharmacokinetics results indicate no food effect
* FDA has completed its review of our request and has granted a waiver of $1,187,100 application fee for Rexista XR
* Food effect study showed that Rexista XR can be administered with or without a meal
* Company plans to file NDA for Rexista XR in August of 2016 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
© Thomson Reuters 2017 All rights reserved.